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r e s p i r a t o r y i n v e s t i g a t i o n 5 3 ( 2 0 1 5 ) 1journal homepage: www.elsevier.com/locate/resinvEditorialSearching Hidden Truth behind Clinical TrialsGlobal clinical trials that previously focused on common
diseases are now designed to study rare lung diseases [1].
Although study of rare lung disease is of signiﬁcant clinical
value, various limitations, such as differences in diagnostic
modalities and insurance systems, are yet to be overcome. In
cross-cultural studies, efﬁcacy should be objectively evalu-
ated as the primary endpoint, rather than subjective mea-
sures, which are reported by the patient, such as quality of
life (QOL). A central review of the assessment is normally
performed for every clinical trial in order to ensure accurate
diagnosis. With regard to the risk–beneﬁt ratio, a periodical
assessment of the risk–beneﬁt balance is required to ensure
the safety of enrolled patients during the trial, which may be
the sponsor's responsibility.
Pharmaceutical companies normally design clinical trial
protocols, which has a positive outcome. Therefore, these
companies need to acquire a mandatory IPF sub-population
for a candidate agent.
This sub-population may be different from IPF patients
covered glorious diversity in the real world. Large-scale trials
with interferon gamma failed to produce signiﬁcant results [2].
The candidate agent is expected to beneﬁt a larger population
of IPF patients; however, the sub-population was only bene-
ﬁtted at predeﬁned endpoints. These results revealed that
statistically signiﬁcant risks and beneﬁts were experienced by
the sub-population of IPF patients. The beneﬁts and risks
during treatment with anti-ﬁbrotic agents have been recently
studied in certain IPF phenotypes.
The results of a severity grading method in Japan revealed
that the clinical features of IPF vary during disease progres-
sion [3]. A majority of clinical trials have enrolled mild to
moderate IPF patients in order to obtain a safe positive
outcome with regard to the primary endpoint. How do we
treat the remaining IPF patients using this candidate agent?In other words, how do we obtain proof of efﬁcacy of these
trials for other IPF patients outside this study? To address
these questions, observational analysis is essential even in a
trial-directed proof of concept (POC) [4].
Although translational research based on basic research has a
scientiﬁc basis, observational research is essential for live clinical
practice. Instead of conducting studies on single molecular
inhibition, reverse-translational research based on a clinical
observational process, which leads to regulatory science, along
with poly-pharmacological logistics is required [5].
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